Clinical Trial Update: Anemia Study in Chronic Kidney Disease (CKD) : Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor (PHI) Daprodustat -Forearm Blood Flow (ASCEND-FBF) [Phase 2]

View source ↗

Summary

Phase 2 trial investigating daprodustat, a prolyl hydroxylase inhibitor, for anemia in chronic kidney disease, terminated with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anemia
• Chronic Kidney Disease

Drugs mentioned

• Daprodustat (daprodustat)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Anaemia | Phase 2 | Status: TERMINATED | Results posted: 2021-07-21